CV Sciences Sales Dip, Net Loss Narrows Amid Regulatory Headwinds

TL;DR

**CVSI is bleeding cash and facing a major regulatory cliff, making it a risky bet despite a narrower net loss.**

AI Summary

CV Sciences, Inc. reported a net loss of $382,000 for the three months ended September 30, 2025, a slight improvement from the $456,000 net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $752,000, significantly better than the $1,668,000 loss in the prior year, partly due to a $522,000 benefit from the reversal of accrued payroll taxes. Product sales, net, decreased to $3.256 million for the three months ended September 30, 2025, from $3.865 million in 2024, representing a 15.8% decline. Year-to-date product sales also fell to $10.482 million from $11.821 million, a 11.3% decrease. The company's cash position declined from $454,000 at December 31, 2024, to $381,000 at September 30, 2025, and it generated negative cash flows from operations of $53,000 for the nine months ended September 30, 2025. A significant risk identified is new federal legislation, effective November 13, 2026, prohibiting the sale of hemp-derived products with over 0.4 milligrams of total THC per container, which could impact product offerings. The company secured $300,000 in net proceeds from a secured promissory note in October 2025 to fund operations and growth initiatives.

Why It Matters

CV Sciences' continued net losses and declining revenue, coupled with a precarious cash position, signal significant challenges for investors. The upcoming federal legislation on THC content, effective November 13, 2026, poses a substantial competitive threat, potentially forcing a costly overhaul of product lines or market exit for certain offerings. This regulatory shift could impact customer access to current products and create uncertainty for employees in product development and sales. The company's reliance on additional investment capital to fund operations highlights its fragile financial health, making it a high-risk proposition in a rapidly evolving regulatory landscape.

Risk Assessment

Risk Level: high — The company reported negative cash flows from operations of $53,000 for the nine months ended September 30, 2025, and an accumulated deficit of $87.7 million, raising substantial doubt about its ability to continue as a going concern. Furthermore, new federal legislation effective November 13, 2026, will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container, posing a significant operational and revenue risk.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the company's persistent losses, declining sales, and the looming regulatory threat to its core product offerings. The recent $300,000 capital injection is a short-term fix, not a sustainable solution to its going concern issues.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$10.482M

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

-$752K

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$381K

revenue Growth

-11.3%

Revenue Breakdown

Key Numbers

• $3.256M — Product Sales, Net (Q3 2025) (Decreased from $3.865M in Q3 2024, a 15.8% decline.)
• $10.482M — Product Sales, Net (YTD Sept 2025) (Decreased from $11.821M in YTD Sept 2024, an 11.3% decline.)
• $382K — Net Loss (Q3 2025) (Improved from $456K net loss in Q3 2024.)
• $752K — Net Loss (YTD Sept 2025) (Significantly improved from $1.668M net loss in YTD Sept 2024.)
• $53K — Net Cash Flows Used in Operating Activities (YTD Sept 2025) (Represents negative cash flow from operations, indicating liquidity strain.)
• $87.7M — Accumulated Deficit (Sept 30, 2025) (Indicates significant historical losses and raises going concern doubts.)
• $381K — Cash (Sept 30, 2025) (Decreased from $454K at Dec 31, 2024, highlighting dwindling liquidity.)
• $300K — Net Proceeds from Secured Promissory Note (Oct 2025) (Recent capital injection to fund operations, but a short-term solution.)
• 0.4 milligrams — THC Limit (New federal legislation effective Nov 13, 2026, impacting hemp-derived products.)

Key Players & Entities

• CV Sciences, Inc. (company) — registrant
• Cultured Foods Sp. z.o.o. (company) — acquired European manufacturer
• Elevated Softgels LLC (company) — acquired manufacturer of encapsulated softgels and tinctures
• SEC (regulator) — Securities and Exchange Commission
• $382,000 (dollar_amount) — net loss for Q3 2025
• $752,000 (dollar_amount) — net loss for nine months ended Sept 30, 2025
• $3.256 million (dollar_amount) — product sales, net for Q3 2025
• $10.482 million (dollar_amount) — product sales, net for nine months ended Sept 30, 2025
• $300,000 (dollar_amount) — net proceeds from secured promissory note in October 2025

FAQ

Risk Factors

• New THC Legislation Impact [high — regulatory]: Federal legislation effective November 13, 2026, will prohibit the sale of hemp-derived products with over 0.4 milligrams of total THC per container. This poses a significant risk to CV Sciences' product offerings and revenue streams.
• Dwindling Cash Reserves [high — financial]: Cash position decreased from $454,000 at December 31, 2024, to $381,000 at September 30, 2025. This declining liquidity, coupled with negative operating cash flow, raises concerns about the company's ability to fund ongoing operations.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $87.7 million as of September 30, 2025. This indicates a history of significant losses and contributes to going concern doubts.
• Declining Sales Performance [medium — operational]: Product sales have decreased by 15.8% in Q3 2025 and 11.3% year-to-date. This downward trend in revenue generation requires careful management and strategic adjustments.
• Reliance on Debt Financing [medium — financial]: The company secured $300,000 in net proceeds from a secured promissory note in October 2025. While this provides immediate liquidity, it represents a short-term solution and adds to the company's debt obligations.

Industry Context

The hemp-derived CBD market is highly competitive and subject to evolving regulatory landscapes. Recent legislative changes, such as the upcoming THC limit, are creating uncertainty and could lead to market consolidation. Companies like CV Sciences must navigate these regulatory shifts while facing declining sales and pressure on margins.

Regulatory Implications

The new federal legislation effective November 13, 2026, imposing a 0.4 mg total THC per container limit on hemp-derived products, poses a significant existential threat to CV Sciences' current product portfolio. Compliance will require substantial product reformulation or a pivot to entirely new product categories.

What Investors Should Do

1. Monitor regulatory developments closely.
2. Assess the company's ability to adapt product offerings.
3. Analyze cash burn and future funding needs.

Key Dates

• 2025-11-13: Effective date of new federal legislation on THC limits — This date marks the implementation of new regulations that will significantly impact the sale of hemp-derived products, potentially affecting CV Sciences' core business.
• 2025-10-01: Secured Promissory Note — The company raised $300,000 in net proceeds, providing a short-term capital injection to support operations and growth initiatives.
• 2025-09-30: End of Q3 2025 — Reporting period for the latest 10-Q, showing a net loss of $382,000 and declining cash reserves.
• 2024-12-31: End of Fiscal Year 2024 — Reference point for cash position, which was $454,000 at this date, prior to the decline observed in Q3 2025.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, less any cumulative net income. (Indicates the company's historical unprofitability and potential going concern issues.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Shows the company's profitability (or lack thereof) for the reported periods.)

Net Proceeds

The amount of money received from a sale or issuance of securities after deducting any associated fees or expenses. (Represents the actual cash raised by the company from the promissory note.)

Hemp-Derived Products

Products manufactured from the hemp plant, which is legally defined as cannabis with a THC content of 0.3% or less. (The core product category for CV Sciences, directly impacted by upcoming regulatory changes.)

Total THC

The sum of tetrahydrocannabinol (THC) content in a product, including delta-9-THC and other THC isomers. (The key metric in the new federal legislation that will limit product offerings.)

Year-Over-Year Comparison

Compared to the prior year, CV Sciences has seen a reduction in its net loss for both the third quarter ($382K vs $456K) and year-to-date ($752K vs $1.668M), partly due to a payroll tax benefit. However, product sales have declined by 15.8% in Q3 and 11.3% year-to-date, and cash reserves have dwindled from $454K to $381K. A new, significant regulatory risk concerning THC limits has emerged, effective in late 2026.

Key Financial Figures

• $0.0001 — and outstanding common stock, par value $0.0001 per share. CV SCIENCES, INC. FORM 1

Filing Documents

• cvsi-20250930.htm (10-Q) — 2413KB
• cvsi-ex31_1.htm (EX-31.1) — 15KB
• cvsi-ex31_2.htm (EX-31.2) — 15KB
• cvsi-ex32_1.htm (EX-32.1) — 7KB
• cvsi-ex32_2.htm (EX-32.2) — 7KB
• 0001193125-25-280515.txt ( ) — 9431KB
• cvsi-20250930.xsd (EX-101.SCH) — 1109KB
• cvsi-20250930_htm.xml (XML) — 1687KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3. Quantitative and Qualitative Disclosure About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosure 32 Item 5. Other Information 32 Item 6. Exhibits 33

– FINA NCIAL INFORMATION

PART I – FINA NCIAL INFORMATION

Financia l Statements (unaudited)

Item 1. Financia l Statements (unaudited) CV SCIENCES, INC. CONDENS ED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except per share data) September 30, 2025 December 31, 2024 Assets Current assets: Cash $ 381 $ 454 Accounts receivable, net 405 522 Inventory 4,080 4,897 Prepaid expenses and other 231 370 Total current assets 5,097 6,243 Property and equipment, net 349 399 Right of use assets 410 94 Intangibles, net 82 93 Goodwill 1,010 971 Other assets 47 127 Total assets $ 6,995 $ 7,927 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,214 $ 1,925 Accrued expenses 2,874 3,424 Current portion of operating lease liability 247 83 Current portion of long-term debt, net of debt issuance costs 451 677 Total current liabilities 4,786 6,109 Operating lease liability 162 19 Debt, net of debt issuance costs 504 — Deferred tax liability 4 4 Total liabilities 5,456 6,132 Commitments and contingencies (Note 10) Stockholders' equity Preferred stock, par value $ 0.0001 ; 10,000 shares authorized; 1 share issued as of September 30, 2025 and December 31, 2024; and no shares outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, par value $ 0.0001 ; 790,000 shares authorized as of September 30, 2025 and December 31, 2024; 184,264 shares issued and outstanding as of September 30, 2025 and December 31, 2024 18 18 Additional paid-in capital 89,207 88,773 Accumulated deficit ( 87,733 ) ( 86,981 ) Accumulated other comprehensive income (loss) 47 ( 15 ) Total stockholders' equity 1,539 1,795 Total liabilities and stockholders' equity $ 6,995 $ 7,927 See accompanying notes to the unaudited condensed consolidated financial statements. 1 CV SCIENCES, INC. CONDENSED CONSOLIDATED STATEME NTS OF OPERATIONS (UNAUDITED) (in

View Full Filing

View this 10-Q filing on SEC EDGAR